CORRECTION: Ethiopia/AstraZeneca breast cancer project

24 March 2008

In our report on the five-year breast cancer program organized by the Anglo-Swedish drug major AstraZeneca, the Ethiopian Ministry of Health and health care access campaign group Axios (Marketletter March 17), we incorrectly stated that "five-year findings" from the program had been published in the journal Clinical Oncology. In fact, the program was launched in 2005 and has reported on its first three years of operation at the Tikur Anbessa University. We are pleased to set the record straight and apologize for our error.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight